CeliVax Technology
Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases
Original CeliVax Technology
Antigen Presenting Cells
CeliVax uses B cells, NK cells and monocytes as APCs.
- Cellid developed the world’s first technology of utilizing B cells, NK cells and monocytes as high-efficiency APC.
- A sufficient amount of B cells, NK cells and monocytes can be easily collected from peripheral blood, which makes the drug manufacturing process fast and robust.
- With an appropriate adjuvant, B cells, NK cells and monocytes can stimulate T cell activation as efficiently as dendritic cells.
